TFEB AAV-based gene therapy / Coave Therap, University of Bordeaux - LARVOL DELTA

Coave Therapeutics Receives Grant from the ALS Association to Advance its CTx-TFEB Program as a Potential Treatment for All Forms of ALS (GlobeNewswire) - "Coave Therapeutics...is delighted to announce that it is one of six organisations sharing $2.9 million in grants from the ALS Association that support the advancement of novel therapies for the treatment of amyotrophic lateral sclerosis (ALS). The grant, which will support the development of Coave’s CTx-TFEB program through to preclinical proof-of-concept, has been made through the Association’s Lawrence and Isabel Barnett Drug Development Program....CTx-TFEB is a novel genetic medicine approach designed by Coave to promote autophagy in ALS patients irrespective of genetic subtype, offering the possibility of creating a pan-ALS therapy."

Financing • Preclinical • Amyotrophic Lateral Sclerosis • CNS Disorders